Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Lancet. 2024 Mar 23;403(10432):1164-1175. doi: 10.1016/S0140-6736(23)02844-1. Epub 2024 Feb 22.
Lancet. 2024.
PMID: 38402887
Free PMC article.
Clinical Trial.
Novel oral poliovirus vaccine type 2 is an important eradication tool, but reaching every last child remains vital.
Kotei L, Clarke E.
Kotei L, et al.
Lancet Infect Dis. 2024 Apr;24(4):337-339. doi: 10.1016/S1473-3099(23)00781-8. Epub 2024 Jan 18.
Lancet Infect Dis. 2024.
PMID: 38246192
No abstract available.
Item in Clipboard
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study.
Bashorun AO, Kotei L, Jawla O, Jallow AF, Saidy AJ, Kinteh MA, Kujabi A, Jobarteh T, Kanu FJ, Donkor SA, Ezeani E, Fofana S, Njie M, Ceesay L, Jafri B, Williams A, Jeffries D, Kotanmi B, Mainou BA, Ooko M, Clarke E.
Bashorun AO, et al. Among authors: kotei l.
Lancet Infect Dis. 2024 Apr;24(4):417-426. doi: 10.1016/S1473-3099(23)00631-X. Epub 2024 Jan 15.
Lancet Infect Dis. 2024.
PMID: 38237616
Free PMC article.
Item in Clipboard
Cite
Cite